Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brilacidin vs Daptomycin in ABSSSI
NCT02052388Phase 2Completed
- Sponsor
- Innovation Pharmaceuticals Inc.
- Start
- Feb 2014
- Primary completion
- Oct 2014
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of brilacidin in acute bacterial skin and skin structure infection (ABSSSI) (4 arms), sponsored by Innovation Pharmaceuticals Inc. Primary endpoint: Early clinical response. Started Feb 2014; status: completed.
02
Drugs
brilacidin
03
Conditions
acute bacterial skin and skin structure infection (ABSSSI)
Beyond the preview
Go deeper on NCT02052388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02052388.